In view of these compelling data, it cannot surprise that preventive measures have been already taken (UK, Switzerland) or are lively discussed (Germany, USA) to restrain female donors with a history of pregnancy from plasma donation, to exclude plasma from females with pregnancy history from quarantine plasma production or to disperse whole blood-derived platelets for pooled PC predominantly in male plasma. In Germany, several German Red Cross (GRC) and university clinic blood donation services have started to test large cohorts of females with a history of pregnancy for HLA as well as HNA antibodies [6] [7] [8] . In this situation one might wonder why the organizers of the StKB-Zukunftsworkshop Hämo-und Zelltherapie have found it necessary to hold an international symposium on TRALI. In our view the pathogenetic background of TRALI is not as clear as haemovigilance and surveillance study data suggest. For instance, the outstanding role of LC-AB as a decisive trigger for TRALI can be easily constrained by simple calculations on the frequency of transfusions of plasma-rich blood components containing LC-AB. For Germany, we have based such calculations on the following assumptions and, if possible, on existing data: According to the announcements to the PEI under the terms of § 21 TFG [9] , the number of FFP, definitely transfused to patients, has a stable level around 1. As the registration rate for transfusions to patients varies from 60 to 70% per year, a total number of 1.2 Mio transfusions of plasmarich blood components per year appears to be a very conservative calculation base. For Germany, no reliable data exist for the proportion of female blood donors with a history of at least one pregnancy. However, we have found one large study who evaluated the proportion of female WB and PC donations with previous allo-exposure (pregnancies and blood transfusion) out of 6 large geographical areas in the USA for the year 2006 [10] . Related to a total number of 1.02 Mio whole blood / PC donations, the authors found a female donation rate of 47% (0.476 Mio female donations) 2.2% of which had a history of blood transfusion and 59% of which had at least one previous pregnancy. The latter number fits well to results of an investigation on the attitude of women in Germany to children and childlessness that revealed a rate of 35% childlessness in women beyond 35 years of age [11] . There are two German studies that allow a relatively reliable estimation of the proportion of LC-AB carriers among previously pregnant female blood donors. The GRC Blood Donation Services Hagen and Bad Kreuznach investigated 2,752 female donors with ≥1 pregnancy and 1,120 females with ≥2 pregnancies. The rate of LC-AB carriers with HLA class I antibodies was 7.8 or 9.6%. Either alone or additionally to the HLA class I antibodies, a number of women had HLA class II antibodies (45/812 women; 5.5%), and a small proportion of HNA antibody carriers (16/2,752 women; 0.6%) was also detected. For the purpose of our calculations a LC-AB carrier rate of 9% was assumed as a realistic value. Based on these assumptions and data, we calculated the number of transfusions of LC-AB-containing plasma-rich blood components for Germany for the period 1992 through 2006 and for Hanover Medical School for the year 2006; the results are given in table 1. It must be pointed out that the calculated numbers of 449,000 transfused plasma-rich blood components for Germany for the 15-year period 1992-2006 represent least numbers as roughly 30% of institutions that apply transfusions do not announce them to the PEI. Moreover, approximately 600 LC-AB-containing plasma-rich blood components must have been applied at Hanover Medical School in 2006, but no TRALI cases were observed.
One might argue that the rare coincidence between transfusion of a LC-AB-containing plasma-rich blood components and TRALI must be due to the rare coincidence of a LC-AB and its cognate antigen in the patient. However, for several reasons this is also no convincing objection. First, most LC-AB carriers usually have several rather than only one LC-AB. Second, despite the high polymorphism that characterizes the HLA system, many important HLA antigens show phenotype frequencies above 10% (e.g. HLA-A1, HLA-B7, HLA-DR11 and others) or even far above 10% (e.g. HLA-A2). Third, in contrast to the HLA system, the HNA system shows a low polymorphism [12] , and most HNA antigens are widely spread in the general population (e.g. HNA-1a approximately 55%, HNA-3a >90%). Thus, the passive transfer of LC-AB via a plasma-rich blood component into a patient with a cognate antigen cannot be a rare event. This view is supported by a number of look-back studies from Poland [13] and the USA [14, 15] . These studies were prompted by single cases of severe TRALI ('index cases'); each of them was caused by longterm female blood donors with a history of blood donation of up to 16 years. In these donors LC-AB were detected when the diagnosis 'TRALI' in the index case was made. As shown in table 2, over the years these donors had given a total 623 blood components. Of these, the majority (322/623; 52%) were plasma-rich blood components. In the study of Toy et al. [15] , HLA typing of the transfusion recipients was available in 55 of 103 patients. As the donor of this study was broadly sensitized, 54 of the 55 transfusion recipients showed at least one cognate antigen (and many of these recipients presented even several cognate antigens), but no TRALI. In the study of MaÊlanska et al. [13] out of a group of 62 LC-AB-positive female donors with a total of 296 blood products, one RCC produced severe TRALI [13] . The donor of the RCC had 12 additional transfusion recipients without TRALI. From 26 of the 61 polish female donors without evidence of TRALI in transfusion recipients, HLA typing results of transfusion recipients and specific HLA antibodies in the donors could be retrieved. In 11 of these 26 donor-transfusion recipient pairs (42%), a cognate HLA antigen in the recipient was demonstrable, but no TRALI. What can we learn from these calculations and look-back study results? Many case reports are suggestive for LC-AB to n.a. = Not available. 
